NCT05445557: A reported trial by Raziel Therapeutics Ltd.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05445557 |
|---|---|
| Title | A Double-Blind, Placebo-Controlled Phase Followed by An Open-Label Phase to Evaluate the Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 10, 2022 |
| Completion date | Oct. 20, 2022 |
| Required reporting date | Oct. 20, 2023, midnight |
| Actual reporting date | June 26, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |